You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Prediction of Strutural Response and Fluid-Induced Vibration in Turbomachinery

    SBC: CFD RESEARCH CORPORATION            Topic: T102

    Advanced turbomachinery components play a critical role in launch vehicle and spacecraft liquid rocket propulsion systems. To achieve desired efficiencies, extremely tight tolerances are often imposed between inducer blades and shrouds or other system components which sets up strong interactions that influence both the aerodynamics and the structural performance of blades and vanes. These transien ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  2. Unified In-Space Propulsion Framework for Prediction of Plume-Induced Spacecraft Environments

    SBC: CFD RESEARCH CORPORATION            Topic: T102

    Chemical contamination of spacecraft components as well as thermal and force loading from firing liquid propellant thrusters are critical concerns for in-space propulsion applications. Gas molecular contamination and liquid droplet deposition due to incomplete combustion threaten to damage surface materials, sensitive instruments and optical sensors, and poses major risks for mission success. Liqu ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  3. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Optimization of a computationally designed antiviral for influenza

    SBC: Virvio Inc            Topic: NIAID

    DESCRIPTION provided by applicant Influenza is a leading cause of death and morbidity in the US resulting in up to deaths hospitalizations and andgt $ billion in expenses per year Current antivirals incur high resistance rates and have low efficacy so there is a crucial need to develop better approaches to protect from seasonal influenza and future pandemics We aim to ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Microfluidic Platform for Stem Cell Applications

    SBC: Nortis, Inc.            Topic: NCATS

    DESCRIPTION provided by applicant The emerging field of stem cell therapy has the potential to transform medicine forever However a major bottleneck for bringing stem cell therapies to the patient is the lack of adequate in vitro assays for the study of stem cell quality Critical test criteria are efficacy pluripotency prior to the differentiation process and safety lack of tumorigenicity ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Clonotyping Technology for Prediction of Antibiotic Resistance

    SBC: ID GENOMICS SPC            Topic: NIAID

    DESCRIPTIONprovided by applicantThe primary goal of this proposal is to develop and finalize configuration of a rapid molecular diagnostics test to predict antibiotic resistance of th major human uropathogensEscherichia coliKlebsiella pneumoniaeEnterobacter spp and Pmirabilisby determining the sub species clonal identityclonotypeof the infecting bacteria directly from urine samplesCurrentlythe emp ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species

    SBC: ILLIONIX, LLC            Topic: 113

    DESCRIPTION provided by applicant Cardiovascular diseases and Asthma affects between and million people in the United States including million children during the past years its incidence worldwide has doubled Asthma is responsible for million person days of restricted activity and deaths per year amounting to $ billion in direct heath related costs there is uncertainty about the specific factors ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of a novel cancer immunotherapeutic antibody for human use

    SBC: CANCURE LLC            Topic: 102

    ABSTRACT The goal of this application is to evaluate the cancer therapeutic feasibility of CanCureandapos s humanized first in class immunostimulatory monoclonal antibody mAb huB G the Product also names CuraB During cancer development in response to oncogenic insult or stress almost ALL human cancer cells are induced to express a SURFACE molecule MIC MHC I chain related Molecule wh ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus

    SBC: KINETA, INC.            Topic: R

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a chronic multisystem autoimmune disease with poorly understood etiology and pathogenesis and for which adequate treatment options are limited Although dysregulated production of autoantibodies and immune complex deposition are considered hallmarks of SLE considerable evidence supports the hypothesis that auto reactive ly ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government